Celularity Inc.
NASDAQ:CELUBiotechnology
+$1.22 today
- Market cap
- $52.97M
- Beta
- 0.54
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$3.58
Volume 0.00M
Average 0.13M
CELU Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Celularity Inc.NASDAQ: CELU
Investing Cash Flow · Q4 FY2025 · quarter ended Dec 2025
Investing cash flow turns positive
Q4 FY2025 investing cash flow was $0, compared with -$1.56M a year earlier. Trailing-twelve-month investing cash flow was $0.
Context
- Investing cash flow amounted to 0.0% of revenue in FY2025, down 0.9 pp from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly investing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 514K | +112.7% |
| FY2023 | 2023-12-31 | (4.05M) | +22.7% |
| FY2022 | 2022-12-31 | (5.24M) | +11.3% |
| FY2021 | 2021-12-31 | (5.9M) | — |
Investing Cash Flow vs competitors
How CELU compares with its peers on the latest reported figures
- CELU's LTM Dec 2025 investing cash flow of $0 is the 2nd largest of the 4 companies compared; the peer median is $0.
- Investing cash flow amounts to 0.0% of revenue for CELU, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $584K | — | -34.3% | 1.7% | |
| LTM Dec 2025 | $0 | -100.0% | — | 0.0% | |
| LTM Dec 2025 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding CELU) | $0 | — | -34.3% | 1.7% | |
Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.12M) | 14.19M | (196.3M) | (57.89M) | (91.72M) |
| Depreciation & Amortization | 8.82M | 9.44M | 11.48M | 7.92M | 7.3M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 3K |
| Stock-Based Compensation | 40.01M | 15.86M | 15.02M | 11.57M | 10.38M |
| Change in Working Capital | (5.71M) | (15.45M) | (6.77M) | 22.2M | 33.59M |
| Accounts Receivables | (1.91M) | (3.58M) | (6.83M) | (3.97M) | 7.55M |
| Inventory | (6.42M) | (16.89M) | (865K) | 6.28M | 10.25M |
| Accounts Payables | 0 | 0 | 0 | 9.24M | 3.13M |
| Other Working Capital | 2.62M | 5.02M | 919K | 10.65M | 12.67M |
| Other Non-Cash Items | (53.1M) | (161.91M) | 137.89M | 9.8M | 27.19M |
| Operating Cash Flow | (110.1M) | (137.88M) | (38.69M) | (6.4M) | (13.25M) |
| Capital Expenditures | (6.2M) | (5.24M) | (4.05M) | (161K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (1.5M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 300K | 0 | 0 | 2.18M | 0 |
| Investing Cash Flow | (5.9M) | (5.24M) | (4.05M) | 514K | 0 |
| Debt Repayment | 0 | 39.2M | 11.31M | 7.1M | (121K) |
| Common Stock Issued | 638K | 53.37M | 5.43M | 58K | 24.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | (5.9M) |
| Other Financing Activities | 97.92M | 27.26M | 7.35M | (459K) | 255K |
| Financing Cash Flow | 98.56M | 119.84M | 24.09M | 6.7M | 18.65M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (17.44M) | (23.27M) | (18.64M) | 814K | 5.4M |
| Free Cash Flow | (116.3M) | (143.11M) | (42.73M) | (6.56M) | (13.25M) |
Celularity Inc.
NASDAQ:CELU
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.